What is precision medicine and how has it evolved over time? Sara Van Driest, MD, PhD Vanderbilt University Medical Center March 2, 2016
|
|
- Toby Adams
- 5 years ago
- Views:
Transcription
1 What is precision medicine and how has it evolved over time? Sara Van Driest, MD, PhD Vanderbilt University Medical Center March 2, 2016
2 What is Precision Medicine Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. diseases.
3 Nothing New Under the Sun It is much more important to know what sort of a patient has a disease than what sort of a disease a patient has. Sir William Osler
4 Francis Collins on getting his genes Politico, Q&A: Francis Collins on high hopes and a made schedule for precision medicine by Arthur Allen, 12/27/2015. analyzed Did it do anything for you personally? Well it did in an odd way I was at higher risk than the average person for Type 2 diabetes... This was six years ago, I was 30 pounds heavier at that point and pretty much having no exercise and a pretty awful diet. That all changed
5 Francis Collins on getting his genes Politico, Q&A: Francis Collins on high hopes and a made schedule for precision medicine by Arthur Allen, 12/27/2015. analyzed Kathy Hudson: He used to live on these really disgusting honeybuns that they sell from the vending machines in Building 31. They were like 700 calories. They were so good... Never again. In other words, getting your SNPs ruined your life? Yes, it made me live a longer and miserable life.
6 Overview Precision Therapeutics Precision Diagnostics Precision Prognostics Looking Ahead
7 Which treatment is best for this disease? Intended Effect No Effect Side Effect Severe Adverse Event
8 Which treatment is best for this patient? Some reasons for variable drug effects: Age, sex Ancestry Drug interactions Environment Diagnosis Genetics Variable drug levels Altered responsiveness
9 Secondary Prevention in Heart Attack
10 Population Benefit of Clopidogrel 30 Days after Stent N Engl J Med. 2005; 352:
11 Individual Benefit of Clopidogrel 30 Days after Stent CYP2C19 Matters High Risk Genotype Lancet October 16; 376(9749):
12 Point of Care Decision Support
13 Percent of Patients What is the impact of genotyping? 100 Percent Treated with Alternative to Clopidogrel Nonactionable Intermediate Metabolizer CYP2C19 Result Poor Metabolizer Clin Pharm Ther Dec 22. doi: /cpt.331.
14 Overview Precision Therapeutics Precision Diagnostics Precision Prognostics Looking Ahead
15 Classifying Malignant Melanoma Historically Microscopic Features UV Exposure Genetic changes BRAF 38% Unknown 40% NRAS 15% GNAq/GNA11 4% KIT 2% CTTNB1 1%
16 Therapeutic BRAF Inhibition pre-treatment post-treatment relapse J Clin Oncol Aug 1;29(22):
17 Overview Precision Therapeutics Precision Diagnostics Precision Prognostics Looking Ahead
18 A Famous Case of BRCA1 Variation and Cancer Prevention New York Times May , A25 Image by Foreign and Commonwealth Office
19 Two Arrhythmia Genes Sequenced from 2,022 Individuals 122 rare variants Variants classified by 3 expert labs The labs don t agree JAMA Jan 5;315(1): JAMA Jan 5;315(1):33-5.
20 Two Arrhythmia Genes Sequenced from 2,022 Individuals Until more is known about the true clinical validity of such pathogenic variants in unselected 122 populations, rare non-synonymous returning results seems variants problematic, at least for these 2 genes and perhaps for others. At a minimum, the language for describing variations Variants predictive classified ability should by be carefully 3 expert calibrated sites to convey, when appropriate, a probabilistic, rather than deterministic, nature. EMR Phenotyping 63 with --William pathogenic Gregory Feero, variants MD, PhD ECG (44) QTc > 500ms (2) < 5% are affected JAMA Jan 5;315(1): JAMA Jan 5;315(1):33-5.
21 Overview Precision Therapeutics Precision Diagnostics Precision Prognostics Looking Ahead
22 A Geographer s View of the World
23 The Precision Medicine View of the World Genomics Health records Microbiome Metabolomics Proteomics mhealth Food deserts Patient Preferences Poverty
24 Precision Medicine Integrates Data Preferences -omics EHRs mhealth Sociocultural determinants of health Comprehensive Recommendation
25 Thank You Many slides courtesy of Dan Roden
Pharmacogenomics with Clopidogrel: Does One Size Fit All?
Pharmacogenomics with Clopidogrel: Does One Size Fit All? Leah A. Sabato, PharmD PGY-1 Pharmacy Practice Resident UC Health - University of Cincinnati Medical Center leah.sabato@uchealth.com April 2015
More informationImplementation of Pharmacogenomics in Clinical Medicine in the USA
Implementation of Pharmacogenomics in Clinical Medicine in the USA Dan M. Roden, MD Senior Vice President for Personalized Medicine Vanderbilt University Medical Center, Nashville, TN The vision "Here's
More informationThe New World of Genomics
The New World of Genomics Amy Sturm, LCGC Associate Professor Department of Internal Medicine The Ohio State University Wexner Medical Center Learning Objectives To define genomic medicine To review early
More informationThe New World of Genomics
The New World of Genomics Amy Sturm, LCGC Associate Professor Department of Internal Medicine The Ohio State University Wexner Medical Center Learning Objectives To define genomic medicine To review early
More informationCS2220 Introduction to Computational Biology
CS2220 Introduction to Computational Biology WEEK 8: GENOME-WIDE ASSOCIATION STUDIES (GWAS) 1 Dr. Mengling FENG Institute for Infocomm Research Massachusetts Institute of Technology mfeng@mit.edu PLANS
More informationBig data vs. the individual liver from a regulatory perspective
Big data vs. the individual liver from a regulatory perspective Robert Schuck, Pharm.D., Ph.D. Genomics and Targeted Therapy Office of Clinical Pharmacology Center for Drug Evaluation and Research Food
More informationHow Can Law and Policy Support Work on Health and Health Care Disparities?
How Can Law and Policy Support Work on Health and Health Care Disparities? Wylie Burke MD PhD Department of Bioethics and Humanities University of Washington Seattle, WA The Precision Medicine Initiative
More informationClinical Trials: Advanced or Metastatic Bladder Cancer Wednesday June 22 nd, 2016 Part III: Question and Answer
Clinical Trials: Advanced or Metastatic Bladder Cancer Wednesday June 22 nd, 2016 Part III: Question and Answer Questions Answered by Andrea Apolo, MD is a Lasker Clinical Research Scholar and tenure-track
More informationJackson Distinguished Professor of Clinical Medicine, Harvard Medical School
Dennis Ausiello, M.D. Founder and Director, Center for Assessment Technology and Continuous Health (CATCH) Physician-in-Chief Emeritus, MGH Jackson Distinguished Professor of Clinical Medicine, Harvard
More informationPrevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D.
Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Hereditary Cancer Center, Peking University Cancer Hospital 1 Breast cancer
More informationHow to use our country pages when researching country related travel health risks
Country pages guide How to use our country pages when researching country related travel health risks Overview We hope you will like the new layout for our country information pages; we have listened to
More informationExample HLA-B and abacavir. Roujeau 2014
Example HLA-B and abacavir Roujeau 2014 FDA requires testing for abacavir Treatment with abacavir is generally well tolerated, but 5% of the patients experience hypersensitivity reactions that can be life
More informationINDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Precision Oncology: Current Applications of omics ACP Arizona Chapter Scientific Meeting, 2014 Arizona State University in Tempe, Arizona Alan Bryce, MD 2012 MFMER slide-1
More informationCardiovascular pharmacogenomics: ready for prime time?
Cardiovascular pharmacogenomics: ready for prime time? Simon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of Pharmacy,
More informationDesign of observational studies: a fresh look at classical designs
Design of observational studies: a fresh look at classical designs TG5: STUDY DESIGN ELIZABETH WILLIAMSON LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE TG5 members Doug Altman Gary Collins Luc Duchateau
More informationThe Patient Perspective: diagnostic Exome Sequencing
1 2 Hello, I m Teresa Kruisselbrink, genetic counselor in the Center of Individualized Medicine. 3 I have nothing to disclose. 4 The title of my talk, The patient perspective; diagnostic whole exome sequencing,
More informationPersonalized Genomic Medicine: What is it? Why should I care? How can I use it?
Friday, October 17, 2014 Olli Lifelong Learning Health Education Series Lunch and Learn UNC-Asheville Campus Lynn G. Dressler, Dr.P.H. Director, Personalized Medicine Mission Health Fullerton Genetics
More informationQuestions for Eric London: Alternative diagnoses for autism
OPINION, Q&A Questions for Eric London: Alternative diagnoses for autism BY JESSICA WRIGHT 2 JANUARY 2015 1 / 7 Deep dive: Listing detailed symptoms rather than assigning a single diagnostic label may
More informationTelepathology 2/17/2011. and The Future of Pathology (or Why did we change our Practice Model) University Health Network IMAGINE3: 3 IMAGINE 2!
Telepathology and The Future of Pathology (or Why did we change our Practice Model) Jagdish Butany, MBBS, MS, FRCPC (a)why did we implement telepathology (WSI) at UHN? Consultant Cardiovascular Pathologist/Director
More informationHost Genomics of HIV-1
4 th International Workshop on HIV & Aging Host Genomics of HIV-1 Paul McLaren École Polytechnique Fédérale de Lausanne - EPFL Lausanne, Switzerland paul.mclaren@epfl.ch Complex trait genetics Phenotypic
More information3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing
UP! UNDERSTANDING PHARMACOGENOMICS (PGX) Robert Pyatt Ph.D., Director Sanford Medical Genetics and Genomics Laboratories and Associate Professor, Dept of Internal Medicine, University of South Dakota April
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationBig Data Course Week 7 Test2Learn TM 5/7/16
The site is http://api.test2learn.com Usernames are first letter of first-name + first 3 letters of last name (i.e. John Smith would be jsmi ) Passwords are the same as the usernames. Everyone will need
More informationStrategies to Reduce Sugar- Sweetened Beverage Consumption: Lessons from New York City
Strategies to Reduce Sugar- Sweetened Beverage Consumption: Lessons from New York City Anne Sperling, MPH Ashley Lederer, MS, RD Bureau of Chronic Disease Prevention NYC Department of Health and Mental
More informationA PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI)
A PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) Sony Tuteja, PharmD, MS Twitter @sony_tuteja Perelman School of Medicine at the University
More informationOutline. Outline. Phillip G. Febbo, MD. Genomic Approaches to Outcome Prediction in Prostate Cancer
Genomic Approaches to Outcome Prediction in Prostate Cancer Phillip G. Febbo, MD Duke Institute for Genome Science and Policy Department of Medicine Department of Molecular Genetics and Microbiology Duke
More informationDevelopment of an iphone app to manage surveillance in women with a BRCA mutation
Development of an iphone app to manage surveillance in women with a BRCA mutation Stephanie A. Cohen, MS, LCGC Genetic Counselor St. Vincent Hospital Indianapolis, IN BRCA-Associated Cancers: Lifetime
More informationRobert Temple, MD Deputy Center Director for Clinical Science Center for Drug Evaluation and Research Food and Drug Administration
Robert Temple, MD Deputy Center Director for Clinical Science Center for Drug Evaluation and Research Food and Drug Administration USE OF REAL WORLD DATA ( BIG DATA ) FOR REGULATORY PURPOSES ISCTM Meeting
More informationBeyond Traditional Treatments: the Roles of Molecular Medicine and Individualized Therapies
Beyond Traditional Treatments: the Roles of Molecular Medicine and Individualized Therapies Michael Maitland, M.D, Ph.D Instructor, Department of Medicine Section of Hematology/Oncology The Committee on
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationDevelopments in Laboratory Genetics
Developments in Laboratory Genetics Rachel Butler rachel.butler@wales.nhs.uk The Impact of Genomics on Public Health Where are we now? Single gene disorders Core disorders Newborn screening (CF, MCAD)
More informationCase Presentation. Case, continued. Case, continued. Case, continued. Lung Cancer in 2014: The New Paradigm
Lung Cancer in 2014: The New Paradigm James J. Stark, MD, FACP Professor of Clinical Internal Medicine Eastern Virginia Medical School August 20, 2014 Case Presentation 62 year old man, former smoker,
More informationTrauma-Informed Primary Care Initiative Learning Community
www. T h e N a t i o n a l C o u n c i l. o r g Trauma-Informed Primary Care Initiative Learning Community Domain 5: Data Collection and Performance Improvement February 9, 2016 Today s Presenters Tony
More informationDeveloping Better Medicine
SURF 2013 Marietta L. Harrison, PhD Director, Oncological Sciences Center in Discovery Park Professor, Medicinal Chemistry and Molecular Pharmacology How we do it today One size fits all Medicines aren
More informationSimon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of
Cardiovascular pharmacogenomics: ready for prime time? Simon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of Pharmacy,
More informationTowards Precision Medicine in Inflammatory Bowel Diseases
Precision Medicine and Biomarkers Leaders Summit. Munich September 13-14, 2018 Towards Precision Medicine in Inflammatory Bowel Diseases ANDRÉS HURTADO-LORENZO, Ph.D. SENIOR DIRECTOR OF TRANSLATIONAL RESEARCH
More informationLessons from a Genomic Screening Program Mike Murray, MD Geisinger Genomic Medicine Institute
Lessons from a Genomic Screening Program Mike Murray, MD Geisinger Genomic Medicine Institute November 1 st 2017 Roundtable on Genomics and Precision Health National Academy of Science Washington DC 1
More informationGENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center
GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center Definitions: DNA: The material found in our cells - the instructions
More informationUpdate on Targeted Therapy in Melanoma
Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1
More informationAssociation mapping (qualitative) Association scan, quantitative. Office hours Wednesday 3-4pm 304A Stanley Hall. Association scan, qualitative
Association mapping (qualitative) Office hours Wednesday 3-4pm 304A Stanley Hall Fig. 11.26 Association scan, qualitative Association scan, quantitative osteoarthritis controls χ 2 test C s G s 141 47
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationPRECISION MEDICINE: THE FUTURE OF PRIMARY CARE
PRECISION MEDICINE: THE FUTURE OF PRIMARY CARE? FRANZ RISCHARD, D.O., M.SC. ASSOCIATE PROFESSOR OF MEDICINE UNIVERSITY OF ARIZONA DIVISION OF PULMONARY AND CRITICAL CARE MEDICINE DIVISION OF TRANSLATIONAL
More informationThank you, Dr. Chalasani. The title for this talk was not my idea. It was Dr. Senior's idea. I am not sure what "Down with the Tower of Babel" means,
Thank you, Dr. Chalasani. The title for this talk was not my idea. It was Dr. Senior's idea. I am not sure what "Down with the Tower of Babel" means, but I am going to try to continue on with that, anyhow.
More informationNautilus & Athletic Journal Articles
Nautilus & Athletic Journal Articles ArthurJonesExercise.com Featuring the Lower Back Machine While the title of this article may lend itself to argument, it is certainly true that the lower back is, at
More informationDining out with your DNA. Tailoring nutrition to fit your genes. Nathan O Callaghan Nutritional Genomics Food and Nutritional Sciences, CSIRO
Dining out with your DNA. Tailoring nutrition to fit your genes Nathan O Callaghan Nutritional Genomics Food and Nutritional Sciences, CSIRO Personalised Nutrition Historically based on Adverse outcomes
More informationCan Big Data Drive Better Care for AKI? What is Big Data and How Can the EMR Work For You?
Can Big Data Drive Better Care for AKI? What is Big Data and How Can the EMR Work For You? AKI & CRRT 2018, March 8, 2018 Scott Sutherland Sean Bagshaw Perry Wilson Overview Introduction to Big Data as
More informationThe Second David Sackett Symposium THE RANDOMIZED TRIAL AS ROYALTY
The Second David Sackett Symposium THE RANDOMIZED TRIAL AS ROYALTY John Concato, MD, MS, MPH Yale University School of Medicine VA Clinical Epidemiology Research Center 27 September 2013 DISCLOSURE John
More information10/19/2017. How Nutritional Genomics Affects You in Nutrition Research and Practice Joyanna Hansen, PhD, RD & Kristin Guertin, PhD, MPH
Disclosures Joyanna Hansen How Affects You in Nutrition Research and Practice Joyanna Hansen, PhD, RD & Kristin Guertin, PhD, MPH Consultant Nutricia North America Research Support Academy of Nutrition
More informationUpdate on the Million Veteran Program Opportunities for Collaboration with WHI T. L. Assimes, MD PhD FAHA
Update on the Million Veteran Program Opportunities for Collaboration with WHI T. L. Assimes, MD PhD FAHA Associate Professor of Medicine, Stanford University Associate Director, Palo Alto VA Health Care
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): In this study the authors analysed 18 deep penetrating nevi for oncogenic genomic changes (single nucleotide variations, insertions/deletions,
More informationCarotid Ultrasound Scans for Assessing Cardiovascular Risk
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/carotid-ultrasound-scans-for-assessing-cardiovascularrisk/4004/
More informationClonal Evolution of saml. Johnnie J. Orozco Hematology Fellows Conference May 11, 2012
Clonal Evolution of saml Johnnie J. Orozco Hematology Fellows Conference May 11, 2012 CML: *bcr-abl and imatinib Melanoma: *braf and vemurafenib CRC: *k-ras and cetuximab Esophageal/Gastric: *Her-2/neu
More informationGuidelines PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42. Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct
PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42 Preoperative, Intraoperative, and Postoperative Factors Associated with Perioperative Cardiac Complications in Patients Undergoing Major Noncardiac
More informationMedical Policy Title GENOTYPING URIDINE DIPHOSPHATE GLYCURONOSYLTRANSFERASE (UGT1A1) FOR PATIENTS TREATED WITH IRINOTECAN Policy Number 2.02.
Page: 1 of 5 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title GENOTYPING URIDINE DIPHOSPHATE GLYCURONOSYLTRANSFERASE (UGT1A1) FOR Policy Number 2.02.34 Category Laboratory Tests Effective Date
More informationFight-or-Flight: Understanding Our Body's Response to Adrenaline
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/primary-care-today/fight-or-flight-understanding-our-bodys-response-toadrenaline/10349/
More informationTQT studies - this is the end!
TQT studies - this is the end! Borje Darpo MD, PhD Associate Professor of Cardiology Chief Scientific Officer icardiac Technologies Yes as the only way to confidently exclude that a new drug has a clinically
More informationSecond Neoplasms Working Group. CCSS Investigators Meeting June 2017
Second Neoplasms Working Group CCSS Investigators Meeting June 2017 Second Neoplasms Working Group Overview Ongoing review, adjudication and entry of reported neoplasms into data set Initial review of
More informationHow many disease-causing variants in a normal person? Matthew Hurles
How many disease-causing variants in a normal person? Matthew Hurles Summary What is in a genome? What is normal? Depends on age What is a disease-causing variant? Different classes of variation Final
More informationYou re listening to an audio module from BMJ Learning. Hallo. I'm Anna Sayburn, Senior Editor with the BMJ Group s Consumer Health Team.
Transcript of learning module Shared decision making (Dur: 26' 13") Contributors: Anna Sayburn and Alf Collins Available online at: http://learning.bmj.com/ V/O: You re listening to an audio module from
More informationSESSION 5 2:20 3:35 pm
SESSION 2:2 3:3 pm Strategies to Reduce Cardiac Risk for Noncardiac Surgery SPEAKER Lee A. Fleisher, MD Presenter Disclosure Information The following relationships exist related to this presentation:
More informationStatistical Essentials in Interpreting Clinical Trials Stuart J. Pocock, PhD
Statistical Essentials in Interpreting Clinical Trials Stuart J. Pocock, PhD June 03, 2016 www.medscape.com I'm Stuart Pocock, professor of medical statistics at London University. I am going to take you
More informationWomen in Science and Engineering: What the Research Really Says. A panel discussion co-sponsored by WISELI and the Science Alliance.
Women in Science and Engineering: What the Research Really Says A panel discussion co-sponsored by WISELI and the Science Alliance. Thursday April 14, 2005 Biotechnology Center Auditorium, University of
More informationGenetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine
Genetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine Lynn Greenhalgh, Macmillan Cancer and General Clinical Geneticist Cancer Genetics Service Cancer is common 1 in
More informationLow-Fat Dietary Pattern Intervention Trials for the Prevention of Breast and Other Cancers
Low-Fat Dietary Pattern Intervention Trials for the Prevention of Breast and Other Cancers Ross Prentice Fred Hutchinson Cancer Research Center and University of Washington AICR, November 5, 2009 Outline
More informationClopidogrel Use in ACS and PCI: Clinical Trial Update
Clopidogrel Use in ACS and PCI: Clinical Trial Update Matthew J. Price MD Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute
More informationCYP2D6 Genotype to Phenotype Standardization Project
CYP2D6 Genotype to Phenotype Standardization Project Project Objectives Determine a strategy for defining CYP2D6 phenotype based on genotype using a modified Delphi method. Standardize phenotype definitions
More informationOverview of the Synthetic Derivative
Overview of the Synthetic Derivative April 22, 2009 Melissa Basford, MBA Program Manager, BioVU and Synthetic Derivative What is BioVU? A biobank intended to support a broad view of biology Currently contains
More informationMEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17
MEDICAL POLICY SUBJECT: MOLECULAR PANEL TESTING OF PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationSupplementary Materials to
Supplementary Materials to The Emerging Landscape of Epidemiological Research Based on Biobanks Linked to Electronic Health Records: Existing Resources, Analytic Challenges and Potential Opportunities
More informationpatients in the era of
Communicating with cancer patients in the era of personalized medicine September 9 th, 2017 Gerald Prager, M.D. Comprehensive Cancer Center Vienna Medical University of Vienna, Austria Gerald Prager, M.D.
More informationA comparative study of different methods for automatic identification of clopidogrel-induced bleeding in electronic health records
A comparative study of different methods for automatic identification of clopidogrel-induced bleeding in electronic health records Hee-Jin Lee School of Biomedical Informatics The University of Texas Health
More informationWhen Do I Consider Myself Cured?
The Melanoma Patient Symposium - Science to Survivorship When Do I Consider Myself Cured? 26 September 2009 Jeffrey E. Gershenwald, MD, FACS Professor of Surgery, Dept. of Surgical Oncology Professor,
More informationPersonalising medicine and mainstreaming genomics: the impact on nursing
Personalising medicine and mainstreaming genomics: the impact on nursing Wednesday 10 th May 2017 Louise Banks, Jenny Hiley Hilary Fanning, Emma Skinner & Charlotte Hitchcock West Midlands Genomic Medicine
More informationDo we all have an actionable genome?
Do we all have an actionable genome? Evidence from, and implications for, registries and electronic health records Professor Harry Hemingway, MD, FFPH, FRCP Director Farr Institute of Health Informatics
More informationLiving Beyond Cancer Skin Cancer Detection and Prevention
Living Beyond Cancer Skin Cancer Detection and Prevention Cutaneous Skin Cancers Identification Diagnosis Treatment options Prevention What is the most common cancer in people? What is the most common
More informationNutrigenomics Revisited: Separating the Hype from the Opportunity
Nutrigenomics Revisited: Separating the Hype from the Opportunity Jeffrey Bland, PhD Founder and Chairman Emeritus The Institute for Functional Medicine Founder & President The Personalized Lifestyle Medicine
More informationOverview of Health IT in Massachusetts: Data to Inform and Improve Performance
Overview of Health IT in Massachusetts: Data to Inform and Improve Performance Office of Economic Analysis, Evaluation and Modeling & State HIE Program December 2011 Chartpack Team Office of Economic Analysis,
More informationView from the Technology Evaluation Center (TEC)
View from the Technology Evaluation Center (TEC) Naomi Aronson, Ph.D. Executive Director, TEC Blue Cross and Blue Shield Association IOM Genomics Workshop December 4, 2007 Overview TEC perspective and
More informationBIOMARKERS IN SEPSIS: DO THEY REALLY GUIDE US? Asist. Prof. M.D. Mehmet Akif KARAMERCAN Gazi University School of Medicine Depertment of Emergency
BIOMARKERS IN SEPSIS: DO THEY REALLY GUIDE US? Asist. Prof. M.D. Mehmet Akif KARAMERCAN Gazi University School of Medicine Depertment of Emergency Medicine 1 NO CONFLICT OF INTEREST 2 We do not fully understand
More informationCritical reading of diagnostic imaging studies. Lecture Goals. Constantine Gatsonis, PhD. Brown University
Critical reading of diagnostic imaging studies Constantine Gatsonis Center for Statistical Sciences Brown University Annual Meeting Lecture Goals 1. Review diagnostic imaging evaluation goals and endpoints.
More informationINTRO. - Team Fraser Coast
INTRO Trying to figure out the basics of CrossFit on your own can be challenging. The web is filled with so many conflicting resources on Functional Fitness 101, finding simple answers as to what it is,
More informationUtility of Pharmacogenomics to Identify and Limit CV Risk. Christopher B. Granger, MD
Utility of Pharmacogenomics to Identify and Limit CV Risk Christopher B. Granger, MD Disclosure Research contracts: AstraZeneca, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company, and Boehringer
More informationCase Studies and Informed Consent. Ashley Cannon, PhD, MS, CGC Genomics Immersion Course 10/14/2015
Case Studies and Informed Consent Ashley Cannon, PhD, MS, CGC Genomics Immersion Course 10/14/2015 Case Study 1 You are studying the gene mutations in the NF1 gene in the hope of establishing genotype-phenotype
More informationGenetics, environment and asthma. Neil Pearce Centre for Public Health Research Massey University Wellington, New Zealand
Genetics, environment and asthma Neil Pearce Centre for Public Health Research Massey University Wellington, New Zealand Rudolf Virchow (1821-1902) published in 1859 the fundamental Die Cellularpathologie
More informationWhy? "the post workout period that results in metabolic disturbance, elevating EPOC,
Q: What do you look for when designing a fat loss training program? Do you look at what people have done in the gyms before, or do you read the research and then try to recreate that? A: The primary goals
More informationPlavix duration of effect
Plavix duration of effect The Borg System is 100 % Plavix duration of effect Jan 20, 2015. If you have had stent placement after balloon angioplasty for coronary artery disease you will be placed on medications
More informationInterviewer: Tell us about the workshops you taught on Self-Determination.
INTERVIEW WITH JAMIE POPE This is an edited translation of an interview by Jelica Nuccio on August 26, 2011. Jelica began by explaining the project (a curriculum for SSPs, and for Deaf-Blind people regarding
More informationNeli Ulrich, MS, PhD Huntsman Cancer Institute, Salt Lake City Using Genetics and Metabolomics to Advance Precision Prevention
Neli Ulrich, MS, PhD Huntsman Cancer Institute, Salt Lake City Using Genetics and Metabolomics to Advance Precision Prevention February 3-5, 2016 Lansdowne Resort, Leesburg, VA Three Highlights Aspirin
More informationIndividualising the Diet for Obesity based on Genetic Testing
Individualising the Diet for Obesity based on Genetic Testing Marilyn Glenville PhD Former President, Food and Health Forum, The Royal Society of Medicine Personalised Nutrition Personalised nutrition
More informationInstructions for Printing Outbreak Scenario Cards:
Instructions for Printing Outbreak Scenario Cards: 1. Print pages 2-14 of this document This document contains 4 scenarios for each outbreak. To determine the number of copies needed, divide the number
More informationMoving Family Health History & Genetic Test Result Data into the Electronic Health Record for Clinical Decision Support
Moving Family Health History & Genetic Test Result Data into the Electronic Health Record for Clinical Decision Support HL7 30 Years of Standards Development HIMSS February 21, 2017 Grant M. Wood Intermountain
More informationPractical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs
Practical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs Joris Vermeesch, Center for Human Genetics K.U.Leuven, Belgium ESHG June 11, 2010 When and
More informationAmerican Psychiatric Nurses Association
Francis J. McMahon International Society of Psychiatric Genetics Johns Hopkins University School of Medicine Dept. of Psychiatry Human Genetics Branch, National Institute of Mental Health* * views expressed
More informationCase-control studies. Hans Wolff. Service d épidémiologie clinique Département de médecine communautaire. WHO- Postgraduate course 2007 CC studies
Case-control studies Hans Wolff Service d épidémiologie clinique Département de médecine communautaire Hans.Wolff@hcuge.ch Outline Case-control study Relation to cohort study Selection of controls Sampling
More informationCHMP Oncology Working Party Workshop on: Histology Independent Indications in Oncology. Non-clinical models: Tumour Models - Proof of Concept
CHMP Oncology Working Party Workshop on: Histology Independent Indications in Oncology Non-clinical models: Tumour Models - Proof of Concept Edward C. Rosfjord Pfizer Worldwide R. & D. 14 December 2017
More information3:54 into mp3 file %20Dr.%20Detterbeck_254205_5_v1.mp3
Welcome to Yale Cancer Answers with your hosts doctors Anees, and Steven Gore. Dr. is Associate Professor of Surgical Oncology and Dr. Gore is Director of Hematological Malignancies at Smilow and an expert
More informationProfessor John F. Peppin, DO, FACP Marian University, College of Osteopathic Medicine, Adjunct Faculty
Professor John F. Peppin, DO, FACP Marian University, College of Osteopathic Medicine, Adjunct Faculty The most important goal of medicine, and health care in general, is to relieve patient suffering.
More informationSURROGATE ENDPOINTS IN ONCOLOGY: OBJECTIVES, METHODOLOGICAL OVERVIEW, AND CURRENT STATUS
SURROGATE ENDPOINTS IN ONCOLOGY: OBJECTIVES, METHODOLOGICAL OVERVIEW, AND CURRENT STATUS Everardo D. Saad, MD Medical Director, IDDI everardo.saad@iddi.com Acknowledgement to Marc Buyse 1 The ideal endpoint
More informationHypertension AN OVERVIEW
AN OVERVIEW Hypertension Your doctor has determined that you have high blood pressure, or hypertension. Although high blood pressure is never really cured, it can be controlled by early detection, lifestyle
More informationRon van Schaik. Pharmacogenetics. London, Oct 8-9, Clinical implementation: a 7 year experience
Ron van Schaik Associate Professor Pharmacogenetics Eur Clin Chem / Advisor EMA - PGWG London, Oct 8-9, 2012 Pharmacogenetics Clinical implementation: a 7 year experience Pharmacogenetics Core Laboratory*
More information